Integra Lifesciences Holdings (IART) Gross Margin (2009 - 2026)

Integra Lifesciences Holdings has disclosed Gross Margin across 18 years of filings, most recently posting 52.47% for Q2 2026.

• In Q2 2026, Gross Margin rose 211.0% year-over-year to 52.47%; the TTM figure through Jun 2026 stood at 52.47% (down 13.0% YoY), while the FY2025 annual figure was 50.86%, down 391.0% from the prior year.
• Gross Margin came in at 52.47% for Q2 2026 at Integra Lifesciences Holdings, down from 55.36% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 62.83% in Q4 2022 to a low of 50.37% in Q2 2025.
• Average Gross Margin over 5 years is 56.05%, with a median of 55.72% recorded in 2024.
• Year-over-year, Gross Margin tumbled 840 bps in 2023 and surged 455 bps in 2026.
• Over 5 years, Gross Margin stood at 62.83% in 2022, then slipped by 9 bps to 57.05% in 2023, then declined by 1 bps to 56.27% in 2024, then decreased by 10 bps to 50.78% in 2025, then grew by 3 bps to 52.47% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 52.47% in Q2 2026, 55.36% in Q1 2026, and 50.78% in Q4 2025.